Pfizer's Oncology Strategy Centers On Three Anchors To Steady The Ship
Ibrance, Xtandi and Bavencio are positioned as three anchor drugs with big market potential and opportunities for expansion, President-Worldwide R&D Mikael Dolsten said at a recent briefing at Pfizer's headquarters.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Seattle Genetics will discontinue all trials of vadastuximab talrine, including the Phase III CASCADE trial in frontline older acute myeloid leukemia patients after a higher rate of deaths was seen.
A cloud hangs over the approval of Roche's Tecentriq in the second line treatment of bladder cancer following the failure of a confirmatory Phase III trial. Meanwhile, rival product Bavencio from Merck KGaA and Pfizer has been granted accelerated approval by the FDA.